DOP2006000051A - Inhibidores de vegf-r2 y métodos - Google Patents

Inhibidores de vegf-r2 y métodos

Info

Publication number
DOP2006000051A
DOP2006000051A DO2006000051A DO2006000051A DOP2006000051A DO P2006000051 A DOP2006000051 A DO P2006000051A DO 2006000051 A DO2006000051 A DO 2006000051A DO 2006000051 A DO2006000051 A DO 2006000051A DO P2006000051 A DOP2006000051 A DO P2006000051A
Authority
DO
Dominican Republic
Prior art keywords
vegf
inhibitors
methods
compounds
formula
Prior art date
Application number
DO2006000051A
Other languages
English (en)
Inventor
David Anthony Barda
Timothy Paul Burkholder
Joshua Ryan Clayton
Yan Hao
Perry Clark Heath
James Robert Henry
John Monte Knobeloch
David Mendel
Johnathan Alexander Mclean
David Michael Remick
Mark Edward Rempala
Zhao-Qing Wang
Yvonne Yee Mai Yip
Boyu Zhong
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2006000051A publication Critical patent/DOP2006000051A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La presente invencion provee compuestos que son inhibidores de VEGF-R2 de formula: asi como metodos usando tales compuestos.
DO2006000051A 2005-02-24 2006-02-22 Inhibidores de vegf-r2 y métodos DOP2006000051A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65598105P 2005-02-24 2005-02-24

Publications (1)

Publication Number Publication Date
DOP2006000051A true DOP2006000051A (es) 2006-08-31

Family

ID=36587138

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2006000051A DOP2006000051A (es) 2005-02-24 2006-02-22 Inhibidores de vegf-r2 y métodos

Country Status (34)

Country Link
US (1) US7666879B2 (es)
EP (1) EP1904494B1 (es)
JP (1) JP5055136B2 (es)
KR (1) KR100904938B1 (es)
CN (1) CN101128461B (es)
AR (1) AR056186A1 (es)
AT (1) ATE490254T1 (es)
AU (1) AU2006216710B2 (es)
BR (1) BRPI0609047A2 (es)
CA (1) CA2599124C (es)
CR (1) CR9331A (es)
CY (1) CY1111154T1 (es)
DE (1) DE602006018615D1 (es)
DK (1) DK1904494T3 (es)
DO (1) DOP2006000051A (es)
EA (1) EA011691B1 (es)
ES (1) ES2354716T3 (es)
HK (1) HK1118284A1 (es)
HR (1) HRP20100677T1 (es)
IL (1) IL184717A (es)
MA (1) MA29433B1 (es)
MX (1) MX2007010326A (es)
NO (1) NO20074666L (es)
NZ (2) NZ560402A (es)
PE (1) PE20061098A1 (es)
PL (1) PL1904494T3 (es)
PT (1) PT1904494E (es)
RS (1) RS51590B (es)
SI (1) SI1904494T1 (es)
TN (1) TNSN07323A1 (es)
TW (1) TW200640924A (es)
UA (1) UA91535C2 (es)
WO (1) WO2006091671A1 (es)
ZA (1) ZA200707136B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5442449B2 (ja) * 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド 新規化合物
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
US8895745B2 (en) * 2006-12-22 2014-11-25 Astex Therapeutics Limited Bicyclic heterocyclic compounds as FGFR inhibitors
CA2679882C (en) 2007-03-08 2015-12-29 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
GB0720041D0 (en) * 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
EP2212323B1 (en) * 2007-10-17 2012-08-15 Novartis AG Imidazo [1,2-a] pyridine derivatives useful as alk inhibitors
GB0810902D0 (en) * 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
ES2477552T3 (es) 2008-09-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Moduladores de la actividad de la aldehidodeshidrogenasa y métodos de uso de los mismos
WO2010062308A1 (en) 2008-10-28 2010-06-03 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
TW201124391A (en) 2009-10-20 2011-07-16 Lundbeck & Co As H 2-substituted-ethynylthiazole derivatives and uses of same
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US8680280B2 (en) 2012-04-02 2014-03-25 Boehringer Ingelheim International Gmbh Process for the manufacturing of CRR inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
US9738636B2 (en) * 2012-09-28 2017-08-22 Vanderbilt University Fused heterocyclic compounds as selective BMP inhibitors
CN104822679B (zh) * 2012-11-29 2016-10-19 霍夫曼-拉罗奇有限公司 咪唑并吡啶衍生物
EP2970124B1 (en) 2013-03-14 2019-05-22 The Board of Trustees of the Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
CN106029660B (zh) 2013-12-16 2019-11-15 阿萨纳生物科技有限责任公司 P2x3和/或p2x2/3化合物和方法
CN103772308B (zh) * 2013-12-31 2015-11-18 北京颖泰嘉和生物科技股份有限公司 5-氨基-3-(1-乙基-1-甲基丙基)异噁唑中间体的制备方法和异噁草胺的制备方法
WO2015187818A1 (en) * 2014-06-03 2015-12-10 The Arizona Board Of Regents On Behalf Of The University Of Arizona Benzimidazole analogues and related methods
EP3169671B1 (en) 2014-07-17 2019-08-21 Sunshine Lake Pharma Co., Ltd. 1-(5-(tert.-butyl)isoxazol-3-yl)-3-(4-((phenyl)ethynyl)phenyl)urea derivatives and related compounds as flt3 inhibitors for treating cancer
CN104163790B (zh) * 2014-08-19 2016-02-10 贵州威顿晶磷电子材料股份有限公司 一种2-氨基-4-甲基-5溴吡啶的制备工艺
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AU2016315881B2 (en) * 2015-09-03 2019-09-19 The Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK1A and uses thereof
AU2017232610B2 (en) * 2016-03-16 2021-07-22 Plexxikon Inc. Compounds and methods for kinase modulation and indications therefore
WO2019178383A1 (en) 2018-03-14 2019-09-19 Vanderbilt University Inhibition of bmp signaling, compounds, compositions and uses thereof
WO2019245590A1 (en) 2018-06-18 2019-12-26 Avista Pharma Solutions, Inc. Chemical compounds
WO2020142559A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Inhibitors of menin-mll interaction
SG11202106304RA (en) 2018-12-31 2021-07-29 Biomea Fusion Llc Irreversible inhibitors of menin-mll interaction
MX2021009082A (es) 2019-01-30 2021-09-08 Avista Pharma Solutions Inc Compuestos quimicos.
EP3917935A4 (en) * 2019-01-30 2022-11-16 Avista Pharma Solutions, Inc. SYNTHESIS PROCESS AND NEW INTERMEDIATES
US20220098204A1 (en) * 2019-02-18 2022-03-31 Shenzhen Targetrx, Inc. Substituted fused aromatic ring derivative, composition and use thereof
MX2022000099A (es) * 2019-06-25 2022-04-27 Sinopsee Therapeutics Compuestos para el tratamiento del cancer.
CN112778294A (zh) * 2021-01-07 2021-05-11 苏州安睿药业有限公司 5-氨基异噁唑衍生物及其在制备多激酶抑制剂中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514971B1 (en) 1996-03-15 2003-02-04 Zeneca Limited Cinnoline derivatives and use as medicine
JP2001518470A (ja) 1997-09-26 2001-10-16 メルク エンド カムパニー インコーポレーテッド 新規な血管形成阻害剤
ES2253233T3 (es) 1999-07-09 2006-06-01 Boehringer Ingelheim Pharmaceuticals Inc. Procedimiento para sintesis de compuestos de urea heteroaril sustituidos.
US6492529B1 (en) * 2000-01-18 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Bis pyrazole-1H-pyrazole intermediates and their synthesis
WO2003005999A2 (en) 2001-07-11 2003-01-23 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediated diseases
JP2003313126A (ja) * 2002-04-23 2003-11-06 Sankyo Co Ltd イミダゾピリジン誘導体を有効成分とする医薬
US7125888B2 (en) * 2002-05-02 2006-10-24 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2003298942A1 (en) * 2002-12-11 2004-06-30 Merck And Co., Inc. Tyrosine kinase inhibitors
WO2004052315A2 (en) * 2002-12-11 2004-06-24 Merck & Co., Inc. Tyrosine kinase inhibitors
US7504412B2 (en) 2003-08-15 2009-03-17 Banyu Pharmaceuticals, Co., Ltd. Imidazopyridine derivatives

Also Published As

Publication number Publication date
US7666879B2 (en) 2010-02-23
ZA200707136B (en) 2008-11-26
CN101128461A (zh) 2008-02-20
CN101128461B (zh) 2010-12-22
KR100904938B1 (ko) 2009-06-29
ES2354716T3 (es) 2011-03-17
RS51590B (en) 2011-08-31
US20090227622A1 (en) 2009-09-10
UA91535C2 (en) 2010-08-10
HRP20100677T1 (hr) 2011-01-31
TNSN07323A1 (en) 2008-12-31
AU2006216710A1 (en) 2006-08-31
WO2006091671A1 (en) 2006-08-31
NO20074666L (no) 2007-11-09
PE20061098A1 (es) 2006-10-20
PT1904494E (pt) 2010-12-23
ATE490254T1 (de) 2010-12-15
EA200701802A1 (ru) 2008-02-28
CA2599124C (en) 2013-08-06
MX2007010326A (es) 2007-10-16
BRPI0609047A2 (pt) 2010-11-16
KR20070099029A (ko) 2007-10-08
NZ560402A (en) 2010-06-25
EP1904494A1 (en) 2008-04-02
CA2599124A1 (en) 2006-08-31
AR056186A1 (es) 2007-09-26
HK1118284A1 (en) 2009-02-06
CR9331A (es) 2008-03-31
IL184717A (en) 2011-11-30
IL184717A0 (en) 2007-12-03
SI1904494T1 (sl) 2011-02-28
CY1111154T1 (el) 2015-06-11
DE602006018615D1 (de) 2011-01-13
JP5055136B2 (ja) 2012-10-24
DK1904494T3 (da) 2011-02-21
PL1904494T3 (pl) 2011-04-29
NZ584753A (en) 2011-06-30
TW200640924A (en) 2006-12-01
JP2008531574A (ja) 2008-08-14
MA29433B1 (fr) 2008-05-02
EP1904494B1 (en) 2010-12-01
AU2006216710B2 (en) 2011-08-11
EA011691B1 (ru) 2009-04-28

Similar Documents

Publication Publication Date Title
DOP2006000051A (es) Inhibidores de vegf-r2 y métodos
PA8667201A1 (es) Nuevos compuestos farmaceuticos
CR11427A (es) 2-fluoro-2 - desoxitetrahidrouridinas como inhibidores de citidina desaminasa
MA32938B1 (fr) Composes organiques
PH12014502697A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
ECSP11011338A (es) Anticuerpos biespecíficos anti-her
CR20120510A (es) Derivados de piperidin-4-il azetidina como inhibidores de jak1
CR11861A (es) Compuestos organicos
IN2012DN03883A (es)
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
MX2010007952A (es) Arilpirrolinas insecticidas.
CR20130045A (es) Compuestos terapéuticos
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
ATE400567T1 (de) Kinaseinhibitoren
MX340831B (es) Composiciones pesticidas.
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
DOP2005000010A (es) Inhibidores de quinasa
UA118201C2 (uk) НОВИЙ ОКТАГІДРОЦИКЛОБУТА[1,2-c;3,4-c']ДИПІРОЛ-2-ІЛ
UY31688A1 (es) Plaguicidas
MA34598B1 (fr) Procédés et compositions pour traiter le cancer du poumon
CR20140135A (es) Nuevos derivados de aril-quinolina
CR10548A (es) 18-metil-19nor-androst-4-en-17, 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas) asi como preparaciones farmaceuticas que los contienen
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7
HK1133642A1 (en) Azaadamantane ester and carbamate derivatives and methods of use thereof
EA201270255A1 (ru) 5-фтор-2-оксопиримидин-1(2h)-карбоксилатные производные